World Population

Covid Vaccine List

A Covid vaccine list provides SARS-COV-2 disease vaccines from various manufactures around the world. Prior to the COVID‑19 pandemic, there was an established body of knowledge about the structure and function of coronaviruses causing diseases like SARS which involved development of various vaccine technologies during early 2020. Many of the vaccine candidates will be made trails before evaluating for the safe usage. For example, many of the vaccines that are studied in the lab and tested before they move into clinical trials in humans. Having lots of different vaccines in development increases the chances that there will be more than one successful vaccines. Vaccine performance will be based on efficacy levels. The below are the covid vaccine brands from different manufacturers.

Covid Vaccine Efficacy

According to healthdata.org, ESTIMATING VACCINE EFFICACY FOR COVID-19 PROJECTIONS for Efficacy at preventing symptomatic disease and Efficacy at preventing infection. Currently, the IHME model uses the following inputs of vaccine efficacy, separated by variant: Importantly, vaccine outcomes do not seem to differ for D614G and B.1.1.7. We assume the efficacy against B.1.351 is the same for P.1, as there are currently very limited data for the P.1 variant, and these two variants have a similar mutation.
B.1.351 was identified in October 2020 in South Africa, and P. 1 was identified in Brazil in December 2020.
B.1.351 - South Africa Variant
P.1. - Brazil Variant
B.1.1.7 - UK Variant
B.1.617 - Indian Variant or Doublt Mutant Variant
VaccinesEfficacy at Preventing disease D614G & B.1.1.7Efficacy at Preventing infection D614G & B.1.1.7Efficacy at Preventing disease B.1.351 & P1Efficacy at Preventing infection B.1.351 & P1
AstraZeneca75%52%10%6%
CoronaVac50%43%38%25%
Janssen72%72%64%42%
Moderna94%85%72%47%
Novavax89%77%49%32%
Pfizer/BioNTech91%86%69%45%
Sinopharm73%63%56%36%
Sputnik-V92%80%70%45%

Viruses constantly change through mutation. Currently all the approved vaccines against COVID-19 were designed to act against the wild-type Wuhan strain of the SARS-CoV-2 virus that causes the disease. A variant has one or more mutations that differentiate it from other variants in circulation. In recent months from November 2020 there are many variants are evolved, initially it was UK, Brazil, and South Africa Variant that are generally more contagious than the wild-type. Later it was New york, double mutant also seen spreading fast.

NameVaccine TypePrimary DevelopersCountry of Origin
Comirnaty (BNT162b2)mRNA-based vaccinePfizer, BioNTech; Fosun PharmaMultinational
Moderna COVID‑19 Vaccine (mRNA-1273)mRNA-based vaccineModerna, BARDA, NIAIDUS
COVID-19 Vaccine AstraZeneca (AZD1222); also known as Vaxzevria and CovishieldAdenovirus vaccineBARDA, OWSUK
Sputnik VRecombinant adenovirus vaccine (rAd26 and rAd5)Gamaleya Research Institute, Acellena Contract Drug Research and DevelopmentRussia
COVID-19 Vaccine Janssen (JNJ-78436735; Ad26.COV2.S)Non-replicating viral vectorJanssen Vaccines (Johnson & Johnson)The Netherlands, US
CoronaVacInactivated vaccine (formalin with alum adjuvant)SinovacChina
BBIBP-CorVInactivated vaccineBeijing Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)China
EpiVacCoronaPeptide vaccineFederal Budgetary Research Institution State Research Center of Virology and BiotechnologyRussia
Convidicea (Ad5-nCoV)Recombinant vaccine (adenovirus type 5 vector)CanSino BiologicsChina
CovaxinInactivated vaccineBharat Biotech, ICMRIndia
WIBP-CorVInactivated vaccineWuhan Institute of Biological Products; China National Pharmaceutical Group (Sinopharm)China
CoviVacInactivated vaccineChumakov Federal Scientific Center for Research and Development of Immune and Biological ProductsRussia
ZF2001Recombinant vaccineAnhui Zhifei Longcom Biopharmaceutical, Institute of Microbiology of the Chinese Academy of SciencesChina, Uzbekistan

Vaccine candidates in development

Vaccine development is the long and complex process, The current system for developing, testing, and regulating vaccines are developed during the 20th century as the groups involved standardized their procedures and regulations.

CandidateMechanismSponsorInstitutionTrialPhase
NVX-CoV2373Nanoparticle vaccineNovavaxNovavaxPhase 3
ZyCoV-DDNA vaccine (plasmid)Zydus CadilaZydus CadilaPhase 3
Corbevax Adjuvanted protein subunit vaccineBiological E, Baylor College of Medicine, Dynavax, CEPIBiological E, BaylorPhase 3
Abdala (CIGB 66)Protein subunit vaccineCenter for Genetic Engineering and BiotechnologyCenter for Genetic Engineering and BiotechnologyPhase 3
VIR-7831Plant-based adjuvant vaccineMedicago; GSK; DynavaxMedicagoPhase 3
CVnCoVmRNA-based vaccineCureVac; GSKCureVacPhase 2b/3
Bacillus Calmette-Guerin (BCG) vaccineLive-attenuated vaccineUniversity of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General HospitalUniversity of Melbourne and Murdoch Children’s Research Institute; Radboud University Medical Center; Faustman Lab at Massachusetts General HospitalPhase 2/3
INO-4800DNA vaccine (plasmid)Inovio PharmaceuticalsCenter for Pharmaceutical Research, Kansas City. Mo.; University of Pennsylvania, PhiladelphiaPhase 2/3
Name to be announcedAdenovirus-based vaccineImmunityBio; NantKwestPhase 2/3
UB-612Multitope peptide-based vaccineVaxxinityUnited Biomedical Inc. (UBI)Phase 2/3
GRAd-COV2Adenovirus-based vaccineReiThera; Leukocare; UnivercellsLazzaro Spallanzani National Institute for Infectious DiseasesPhase 2/3
Name to be announcedRecombinant protein vaccineSanofi; GlaxoSmithKlineVariousPhase 2
BNT162mRNA-based vaccinePfizer, BioNTechMultiple study sites in Europe, North America and ChinaPhase 1/2/3
Soberana 1 and 2Monovalent/conjugate vaccineFinlay Institute of VaccinesFinlay Institute of VaccinesPhase 1/2/3
AdCLD-CoV19Adenovirus-based vaccineCellid; LG ChemKorea University Guro HospitalPhase 1/2a
ABNCoV2cVLP-based vaccineExpreS2ion Biotech; Bavarian Nordic A/SPhase 1/2
NanocovaxRecombinant vaccine (Spike protein)Nanogen BiopharmaceuticalMilitary Medical Academy (Vietnam)Phase 1/2
EuCorVac-19nanoparticle vaccineEuBiologicsEunpyeong St. Mary’s HospitalPhase 1/2
Mambisa (CIGB 669)Protein subunit vaccineCenter for Genetic Engineering and BiotechnologyCenter for Genetic Engineering and BiotechnologyPhase 1/2
IIBR-100Recombinant vesicular stomatitis virus (rVSV) vaccineIsrael Institute for Biological ResearchHadassah Medical Center; Sheba Medical Center HospitalPhase 1/2
Name to be announcedSF9 cell vaccine candidateWest China Hospital, Sichuan UniversityWest China Hospital, Sichuan UniversityPhase 1/2
VLA2001Inactivated vaccineValneva; National Institute for Health Research (NIHR)Multiple NIHR testing sitesPhase 1/2
Name to be announcedAdjuvanted protein subunit vaccineCEPIPhase 1/2
AG0301-COVID19DNA vaccineAnGes, Inc.AnGes, Inc.; Japan Agency for Medical Research and DevelopmentPhase 1/2
GX-19NDNA vaccineGenexinePhase 1/2
ARCT-021 (LUNAR-COV19)Self-replicating RNA vaccineArcturus Therapeutics and Duke-NUS Medical SchoolDuke-NUS Medical School, SingaporePhase 1/2
Name to be announcedInactivated vaccineChinese Academy of Medical Sciences, Institute of Medical BiologyWest China Second University Hospital, Yunnan Center for Disease Control and PreventionPhase 1/2
HDT-301 (HGCO19)RNA vaccineUniversity of Washington; National Institutes of Health Rocky Mountain Laboratories; HDT Bio Corp; Gennova BiopharmaceuticalsPhase 1/2
MRT5500mRNA-based vaccineSanofi, Translate BioPhase 1/2
AV-COVID-19Dendritic cell vaccineAivita Biomedical, Inc.Rumah Sakit Umum Pusat Dr KariadiPhase 1b/2
SpFNSpike ferritin nanoparticle vaccineUS Army Medical Research and Development CommandWalter Reed Army Institute of ResearchPhase 1
KBP-201Protein subunit vaccineKentucky BioProcessing, Inc.Velocity Clinical Research; PMG Research of Winston-Salem; ICON; DM Clinical ResearchPhase 1
MV-014-212Intranasal vaccineMeissa Vaccines, Inc.Johnson County Clin-Trials; Meridian Clinical ResearchPhase 1
PTX-COVID19-BmRNA-based vaccineProvidence Therapeutics; Canadian governmentPhase 1
COVI-VACIntranasal vaccineCodagenix; Serum Institute of IndiaPhase 1
CORVax12DNA vaccine (plasmid)OncoSec; Providence Cancer InstituteProvidence Portland Medical CenterPhase 1
MVA-SARS-2-SModified vaccinia virus ankara (MVA) vector vaccine candidateUniversitätsklinikum Hamburg-Eppendorf; German Center for Infection Research; Philipps University Marburg Medical Center; Ludwig-Maximilians - University of MunichUniversity Medical Center Hamburg-EppendorfPhase 1
COH04S1Modified vaccinia virus ankara (MVA) vector vaccine candidateCity of Hope Medical Center; National Cancer InstituteCity of Hope Medical CenterPhase 1
pVACMulti-peptide vaccine candidateUniversity Hospital TuebingenUniversity Hospital TuebingenPhase 1
AdimrSC-2fProtein subunit vaccineAdimmuneAdimmunePhase 1
bacTRL-SpikeMonovalent oral vaccine (bifidobacteria)SymvivoSymvivo CorporationPhase 1
COVAX-19Monovalent recombinant protein vaccineVaxine Pty Ltd.Royal Adelaide HospitalPhase 1
DelNS1-2019-nCoV-RBD-OPT1Replicating viral vectorXiamen University, Beijing Wantai Biological PharmacyJiangsu Provincial Centre For Disease Control and PreventionPhase 1
UQ-CSL V451Protein subunit vaccineCSL; The University of QueenslandPhase 1
SCB-2019Protein subunit vaccineGlaxoSmithKline, Sanofi, Clover Biopharmaceuticals, Dynavax and Xiamen Innovax; CEPILinear Clinical Research (Australia)Phase 1
VXA-CoV2-1Recombinant vaccine (adenovirus type 5 vector)VaxartVaxartPhase 1
AdCOVIDIntranasal vaccineAltimmune; Summit BiosciencesUniversity of Alabama at BirminghamPhase 1
AAVCOVIDGene-based vaccineMassachusetts Eye and Ear; Massachusetts General Hospital; University of PennsylvaniaPre-clinical
ChAd-SARS-CoV-2-SAdenovirus-based vaccineWashington University School of Medicine in St. LouisWashington University School of Medicine in St. LouisPre-clinical
HaloVaxSelf-assembling vaccineVoltron Therapeutics, Inc.; Hoth Therapeutics, Inc.MGH Vaccine and Immunotherapy CenterPre-clinical
LineaDNADNA vaccineTakis BiotechTakis BiotechPre-clinical
Name to be announcedIi-Key peptide COVID-19 vaccineGenerex BiotechnologyGenerexPre-clinical
Name to be announcedProtein subunit vaccineUniversity of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine CentreUniversity of Saskatchewan Vaccine and Infectious Disease Organization-International Vaccine CentrePre-clinical
Name to be announcedmRNA-based vaccineChulalongkorn University’s Center of Excellence in Vaccine Research and DevelopmentPre-clinical
Name to be announcedgp96-based vaccineHeat BiologicsUniversity of Miami Miller School of MedicinePre-clinical
Name to be announcedInactivated vaccineShenzhen Kangtai Biological ProductsPre-clinical
PittCoVaccRecombinant protein subunit vaccine (delivered through microneedle array)UPMC/University of Pittsburgh School of MedicineUniversity of PittsburghPre-clinical
T-COVIDTMIntranasal vaccineAltimmunePre-clinical
Source: raps

© 2019-2021 populationU, Research papers on Population dynamics and Social affairs